Tim Hague, CEO, Omixon
HLA typings for solid organ make up the majority of all clinical typings around the world, and we are delighted to see how many labs are recognizing that NGS is a technology that can replace their SSO/SSP workflows, and not just their SBT workflows
Budapest, Hungary & Cambridge, MA (PRWEB) September 23, 2016
Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA, announce today that Holotype HLA™ and other Omixon products will be featured in four oral presentations and five poster presentations produced by customers or collaborators at the annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in St Louis, MO. Additionally, Omixon’s Lunch Symposium on Thursday will focus on the ASHI accreditation process for NGS (see a summary of Omixon’s activities below).
Among the oral presentations, Dr. Peter Meintjes, Omixon’s CCO, will present “The Economics of NGS” to highlight how the costs of NGS scale with volume and the number of loci, and how NGS compares to legacy technologies as a suitable replacement for labs with any throughput. The more research-heavy oral presentations will feature Dr. Jamie Duke of The Children’s Hospital of Philadelphia (CHOP) whose topic “Detecting low level clonal somatic mutation in HLA genes using next-generation sequencing in the presence of aplastic anemia” highlights complex cases of challenging samples in which Holotype HLA is superior in its ability to detect low frequency signals in chimeric samples. A third oral presentation by Eszter Lazar-Molnar from ARUP Laboratories tackles a similar issue of detecting low frequency signals due to loss of heterozygosity in her presentation entitled “Resolution of conflicting HLA assignment due to loss of heterozygosity in the HLA region by NGS typing”.
Accreditation and validation will be the major topic of Omixon’s Lunch Symposium, featuring three independent speakers, who will also speak about their experience in working with Omixon. Two HLA lab Directors that have made leading contributions to the ASHI NGS validation/accreditation standards, Dr. Zahra Kashi and Dr. Lee Ann Baxter Lowe will provide their views, as well as Doreen Sese from Yale University – the first lab in the world to become ASHI accredited with NGS for serving only solid organ programs, moving directly from SSO/SSP workflows to NGS without accrediting SBT, acting as a pioneer for other solid organ only labs.
The case for high resolution typing by NGS for solid organ transplantation will be further enhanced by Yanping Huang of CHOP in her oral presentation entitled “Three case reports: NGS-based high resolution HLA typing permits better assessment of donor-recipient compatibility in solid organ transplant”. Her presentation is expected to provide a significant stimulus for more solid organ labs to adopt NGS typing for HLA. Omixon’s CEO, Tim Hague, notes that “HLA typings for solid organ make up the majority of all clinical typings around the world, and we are delighted to see how many labs are recognizing that NGS is a technology that can replace their SSO/SSP workflows, and not just their SBT workflows”.
Tim Hague and Dr. Peter Meintjes will be supported at the event by a six-strong team including Head of Lab and Field Operations, Efi Melista, Market Development Manager, Nora Nagy, and Sales Directors Faisal Mojaddidi and Maggi Woronkowicz, CHS. Dr. Meintjes notes that “The ASHI meeting is an unparalleled opportunity to share in the latest trends through the formal program, informal networking and one-on-one consultative sessions with Omixon”. Rounding out the scientific program for Omixon will be the second convening of Omixon’s Scientific Advisory Board (SAB), Chaired by Professor Dimitri Monos, with contributing SAB Members Prof. Malek Kamoun, Prof. Dominique Charron and Dr. Matthew Anderson.
Omixon at ASHI 2016
Sept. 26-30 | Omixon will be exhibiting at Booth #415 throughout the conference
Sept. 26, 9.30 - 11:00am | Workshop - Introduction to NGS-based HLA Typing (Register here)
Sept. 26, 11:30am - 1pm | Workshop - Resolving Complex Cases of NGS-based HLA Typing (Register here)
Sept. 29, 12:30 - 2:20pm | ASHI 2016 Symposium - NGS Accreditation with ASHI Standards (Register here)
Omixon featured in Oral Presentations
OR31 | P Meintjes et al. (2016) - The economics of next generation sequencing, at 3:30pm on Wed 9/28
OR46 | JL Duke et al. (2016) - Detecting low level clonal somatic mutation in HLA genes using next-generation sequencing in the presence of aplastic anemia, at 4pm on Thurs 9/29
OR48 | E Lazar-Molnar et al. (2016) - Resolution of conflicting HLA assignment due to loss of heterozygosity in the HLA region by NGS typing, at 4:15pm on Wed 9/28
OR53 | Y Huang et al. (2016) - Three case reports: NGS-based high resolution HLA typing permits better assessment of donor-recipient compatibility in solid organ transplant, at 4:15pm on Wed 9/28
Omixon featured in Poster Presentations
P017 | R Pollok (2016) - Automation of HLA-typing using next generation sequencing with Omixon's holotype HLA X2 kit and beckman-coulter's biomek liquid handling system
P056 | CL Saw et al. (2016) - Simultaneous HLA class I and II sequencing by long read-independent circular consensus SMRT technology
P090 | R Ameen et al. (2016) - NGS characterization of HLA haplotypes in multi-generation families of Kuwaiti descent
P091 | T. Profaizer et al. (2016) - Comparison of four HLA next-generation sequencing typing methods
P135 | M Schäfer et al. (2016) - Determination of the whole HLA-DQB1∗ 06: 37 sequence by the combination of long range polymerase chain reaction, next generation sequencing and phasing
About Omixon
Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s flagship product, Holotype HLA™, is the world’s leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 20 hospitals worldwide. Omixon’s research software, HLA Explore™ analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation. For more information, visit the Omixon website.